Full video transcriptClick to expand
Auto-generated transcript of @xclusiveaesthetics's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00I was going to have a little one to bend them off.
- 0:01You know, you saw much of gold, yeah, but has it been good?
- 0:04Yeah.
- 0:05All right, so how you doing?
- 0:07How you feeling?
- 0:07You know, just a new month.
- 0:09So there's a new dose of your shot.
- 0:10This is going to be another step up and see your weight
- 0:13loss journey.
- 0:14So tell me what's been going on last week.
- 0:16I'm doing good.
- 0:17Just working, working, working.
- 0:20I went to the gym three or four times.
- 0:23Process.
- 0:24You know, just getting better each and every day.
- 0:26All right.
- 0:27I'm ready for it.
- 0:28And I was like, so when I was last time you checked in,
- 0:30I was last week.
- 0:31So I was going to start with them one month.
- 0:32Is your appetite?
- 0:34Well, it's 50-50.
- 0:36If I'm working as much, you know, you've
- 0:37got to eat something when you work at work.
- 0:39But it's pretty OK when I get home.
- 0:41And how did you enjoy?
- 0:42I'm going to be 12, kind of helps with metabolism.
- 0:44And it kind of helps, you know, eating weight loss as well.
- 0:47I have much energy.
- 0:48Like when I wake up in the morning,
- 0:49we have a tiredness day.
- 0:50But other than that, I'm pretty OK.
- 0:52I was going to have a little one to bend them off.
- 0:53Yeah.
- 0:54You know, you saw much of gold, yeah.
- 0:55But has it been good?
- 0:57Yeah.
- 0:5739.
- 0:58You start up before you shoot.
- 0:59So you see a lot of total of 2 pounds last week.
Semaglutide 'patient progress' posts: what the science actually says
Quick answer
The video documents a semaglutide follow-up appointment in what appears to be a home or spa-based med spa setting, where the provider is escalating the patient's dose and tracking weekly weight loss of 2 pounds. A secondary injectable, likely vitamin B12, is mentioned as a metabolic and weight loss aid alongside the semaglutide protocol. The patient reports moderate appetite suppression, gym attendance three to four times per week, and some fatigue in the mornings, all of which are consistent with expected early-phase semaglutide response.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Semaglutide 'patient progress' posts: what the science actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Semaglutide 'patient progress' posts: what the science actually says" from Rachel leach. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video documents a semaglutide follow-up appointment in what appears to be a home or spa-based med spa setting, where the provider is escalating the patient's dose and tracking weekly weight loss of 2 pounds.
The reason this review is not generic is the source wording and the canonical claim label "glp1 you can tell he s got that determination to reach his goals." In this clip, the useful excerpt is: "I was going to have a little one to bend them off." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video documents a semaglutide follow-up appointment in what appears to be a home or spa-based med spa setting, where the provider is escalating the patient's dose and tracking weekly weight loss of 2 pounds.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video documents a semaglutide follow-up appointment in what appears to be a home or spa-based med spa setting, where the provider is escalating the patient's dose and tracking weekly weight loss of 2 pounds. A secondary injectable, likely vitamin B12, is mentioned as a metabolic and weight loss aid alongside the semaglutide protocol. The patient reports moderate appetite suppression, gym attendance three to four times per week, and some fatigue in the mornings, all of which are consistent with expected early-phase semaglutide response.
- The STEP 1 trial (Wilding et al., 2021, NEJM) found a mean 14.9% body weight reduction with semaglutide 2.4 mg over 68 weeks, achieved through gradual dose escalation, not rapid increases.
- Weekly weigh-ins can vary by 1 to 3 pounds due to water retention, sodium intake, and digestion, so a single week's result is not a reliable measure of true fat loss.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The STEP 1 trial (Wilding et al., 2021, NEJM) found a mean 14.9% body weight reduction with semaglutide 2.4 mg over 68 weeks, achieved through gradual dose escalation, not rapid increases.
- Weekly weigh-ins can vary by 1 to 3 pounds due to water retention, sodium intake, and digestion, so a single week's result is not a reliable measure of true fat loss.
- B12 injections have no proven benefit for weight loss or metabolism in people who are not B12-deficient, according to a 2019 review in the Journal of Alternative and Complementary Medicine.
- Resistance training during semaglutide therapy helps preserve lean muscle mass, which the drug alone does not protect against losing (Bikou et al., 2023, Nutrients).
- Compounded semaglutide formulations are not equivalent to FDA-approved branded products and should never be presented as interchangeable.
- Appetite suppression described as '50-50' is a commonly reported early-phase response; full appetite reduction typically develops over several weeks after each dose escalation.
- Morning fatigue is a reported side effect in GLP-1 users and may reflect caloric deficit, altered sleep patterns, or the drug's effect on energy homeostasis, not a sign the medication is working better.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @xclusiveaesthetics actually say?
The video shows a nurse practitioner or RN conducting what appears to be a follow-up appointment with a semaglutide patient. The provider mentions a "new dose" as part of a step-up protocol, references something that "helps with metabolism" and "eating weight loss as well," and notes the patient lost "a total of 2 pounds last week." The patient reports going to the gym three or four times and describes his appetite as "50-50." The provider seems to be doing a legitimate check-in, though the audio is garbled in places, making some specific claims hard to pin down. There is a reference to something being "12" that "helps with metabolism" -- likely a vitamin B12 injection, which is commonly bundled with weight loss programs at med spas. The overall framing is positive and motivational, which is fine, but some of the implied claims deserve scrutiny.
Does the science back this up?
The core practice here, titrating semaglutide doses upward over time, is well-supported. The STEP 1 trial (Wilding et al., 2021, NEJM) used exactly this kind of gradual dose escalation to reach the 2.4 mg weekly maintenance dose, finding a mean weight loss of 14.9% over 68 weeks. Two pounds in a single week is on the higher end of short-term results but not impossible, especially early in treatment or after a dose increase. However, the claim about B12 "helping with metabolism" is where things get murky. B12 injections are popular at weight loss clinics, but the evidence that they accelerate metabolism or fat loss in people who are not B12-deficient is essentially nonexistent. A 2019 review in the Journal of Alternative and Complementary Medicine found no robust clinical evidence supporting B12 injections for weight loss in non-deficient individuals. The gym visits, on the other hand, are genuinely relevant. Resistance and aerobic exercise during GLP-1 therapy helps preserve lean mass, which semaglutide alone does not guarantee.
What did they get wrong (or right)?
They got the dose escalation framework right. Stepping up semaglutide doses gradually is standard protocol and reduces gastrointestinal side effects. Credit where it is due. The patient check-in format, asking about appetite, energy, and lifestyle, reflects reasonable clinical monitoring. The provider also appropriately acknowledges the patient is doing the work, not just attributing results to the drug.
Where this gets questionable is the B12 claim. Saying it "helps with metabolism" and "helps with weight loss as well" implies a proven pharmacological benefit that simply is not supported by the literature for non-deficient patients. This is a common upsell in the med spa space. Patients deserve to know that B12 injections may help if they are deficient, but are unlikely to meaningfully move the needle on weight loss otherwise.
The 2-pound weekly loss also needs context. Short-term fluctuations include water weight, bowel content, and sodium intake. A single week's scale number is not a reliable indicator of fat loss. Long-term data matters more.
What should you actually know?
If you are considering semaglutide for weight management, a few things are worth understanding before you book an appointment anywhere.
- Dose escalation is not optional. The STEP trials showed GI side effects, nausea, vomiting, diarrhea, are significantly reduced when doses increase gradually over 16 to 20 weeks. Anyone offering to jump you to a high dose fast is cutting a corner.
- Two pounds a week sounds great, but the average weight loss on semaglutide is closer to 1 to 2 pounds per week early on, slowing over time. The 15% total body weight figure from clinical trials took 68 weeks.
- Exercise matters. Semaglutide can cause loss of lean muscle mass alongside fat. Researchers including Bikou et al. (2023, Nutrients) have noted the importance of resistance training to preserve muscle during GLP-1 therapy.
- B12 injections are not a proven weight loss tool for people with normal B12 levels. If a clinic bundles them into your program without testing your B12 status first, ask why.
- Compounded semaglutide is not the same as FDA-approved brand-name formulations. Anyone suggesting otherwise is not being accurate with you.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Rachel leach · TikTok creator
8.6K views on this video
You can tell he’s got that determination to reach his goals😌💉👏 Super proud of my patient’s progress so far!! #XclusiveAesthetics #Xclusive #Nurse #NurseLife #Entrepreneur #AestheticsNurse #Virginia #Emporia #EmporiaVirginia #SpaAtHome #HealthandBeauty #MedSpa #Health #Beauty #Semaglutide #Hydrate #WeightLoss #WeightLossTreatment #SelfLove #SelfCare #WeightLossConsultation #LosingWeight #SemaglutideShot #HealthyLifestyle #Wellness #HealthyLiving #WeightLossJourney #TryingToLoseWeight #Semag
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?
The STEP 1 trial (Wilding et al., 2021, NEJM) found a mean 14.9% body weight reduction with semaglutide 2.4 mg over 68 weeks, achieved through gradual dose escalation, not rapid increases.
What does the video say about weekly weigh-ins can vary by 1 to 3 pounds due?
Weekly weigh-ins can vary by 1 to 3 pounds due to water retention, sodium intake, and digestion, so a single week's result is not a reliable measure of true fat loss.
What does the video say about b12 injections have no proven benefit for weight loss?
B12 injections have no proven benefit for weight loss or metabolism in people who are not B12-deficient, according to a 2019 review in the Journal of Alternative and Complementary Medicine.
What does the video say about resistance training during semaglutide therapy helps preserve lean muscle mass,?
Resistance training during semaglutide therapy helps preserve lean muscle mass, which the drug alone does not protect against losing (Bikou et al., 2023, Nutrients).
What does the video say about compounded semaglutide formulations?
Compounded semaglutide formulations are not equivalent to FDA-approved branded products and should never be presented as interchangeable.
What does the video say about appetite suppression described as '50-50'?
Appetite suppression described as '50-50' is a commonly reported early-phase response; full appetite reduction typically develops over several weeks after each dose escalation.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Rachel leach, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.